Lisata Therapeutics (LSTA) News Today $2.90 -0.03 (-1.02%) (As of 01:04 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’November 19 at 5:07 PM | markets.businessinsider.comLisata Therapeutics named ‘Specialized BioTherapeutics Company of the Year' at 2024 BioTech Breakthrough AwardsNovember 19 at 10:02 AM | proactiveinvestors.comLisata Therapeutics named ‘Specialized BioTherapeutics Company of the Year' at 2024 BioTech Breakthrough AwardsNovember 19 at 9:39 AM | proactiveinvestors.comLisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year'November 19 at 8:30 AM | globenewswire.comLisata Therapeutics CEO discusses pancreatic cancer trial progress and new collaborations - ICYMINovember 16, 2024 | proactiveinvestors.comLisata Therapeutics Reports Q3 2024 Financial ResultsNovember 13, 2024 | markets.businessinsider.comLisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost ...November 13, 2024 | finance.yahoo.comLisata Therapeutics, Inc. (LSTA) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comEarnings Outlook For Lisata TherapeuticsNovember 12, 2024 | benzinga.comLisata Therapeutics advances clinical trials in Q3 ahead of 'data-rich' 2025November 12, 2024 | proactiveinvestors.comLisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 12, 2024 | globenewswire.comLisata Therapeutics, Valo Therapeutics enter preclinical research collaborationNovember 7, 2024 | markets.businessinsider.comLisata Therapeutics and Valo Therapeutics partner in preclinical study on cancer immunotherapyNovember 6, 2024 | proactiveinvestors.comLisata Therapeutics and Valo Therapeutics Announce Preclinical Research CollaborationNovember 6, 2024 | globenewswire.comLisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024November 6, 2024 | globenewswire.comLisata Therapeutics partners with University of Cincinnati to investigate endometriosis therapy - ICYMINovember 2, 2024 | proactiveinvestors.comLisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor EventsOctober 31, 2024 | globenewswire.comLisata Therapeutics entered research agreement with University of CincinnatiOctober 28, 2024 | markets.businessinsider.comLisata Therapeutics strikes research partnership to investigate new treatment for endometriosisOctober 28, 2024 | proactiveinvestors.comLisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of EndometriosisOctober 28, 2024 | globenewswire.comRAPT Therapeutics (NASDAQ:RAPT) Stock Quotes, Forecast and News SummaryOctober 3, 2024 | benzinga.comLisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor EventsOctober 3, 2024 | finance.yahoo.comAdaptive Biotechnologies (NASDAQ:ADPT) Stock Quotes, Forecast and News SummarySeptember 27, 2024 | benzinga.comStrong Buy Rating for Lisata Therapeutics Backed by Promising Certepetide Clinical PerformanceSeptember 19, 2024 | markets.businessinsider.comLisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER TrialSeptember 17, 2024 | finance.yahoo.comLisata Therapeutics begins treating second cohort of patients in bile duct cancer trialSeptember 17, 2024 | proactiveinvestors.comLisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor EventsSeptember 9, 2024 | globenewswire.comLisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of CholangiocarcinomaSeptember 5, 2024 | finance.yahoo.comLisata Therapeutics' certepetide receives Orphan Drug Designation for cholangiocarcinomaSeptember 5, 2024 | proactiveinvestors.comLisata Therapeutics' Certepetide Granted FDA Orphan Drug Designation for the Treatment of CholangiocarcinomaSeptember 5, 2024 | globenewswire.comWill Lisata Therapeutics (NASDAQ:LSTA) Spend Its Cash Wisely?August 22, 2024 | finance.yahoo.comLisata Therapeutics: Strong Buy Rating on Robust Financials and Promising Clinical TrialsAugust 13, 2024 | markets.businessinsider.comLisata Therapeutics, Inc. (NASDAQ:LSTA) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | msn.comLSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q2 2024August 12, 2024 | investorplace.comLisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 12, 2024 | markets.businessinsider.comLisata Therapeutics coming off strong 2Q performance, CEO saysAugust 12, 2024 | proactiveinvestors.comLisata Therapeutics CMO details pancreatic cancer research collaboration with Haystack Oncology - ICYMIJuly 27, 2024 | proactiveinvestors.comLisata Therapeutics (NASDAQ:LSTA) Stock Quotes, Forecast and News SummaryJuly 22, 2024 | benzinga.comHaystack Oncology And Lisata Therapeutics Partner To Evaluate Efficacy Of Pancreatic Cancer TherapyJuly 19, 2024 | markets.businessinsider.comHaystack Oncology, Lisata Therapeutics Collaborate on Pancreatic Cancer TherapyJuly 19, 2024 | finance.yahoo.comEXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy EfficacyJuly 19, 2024 | msn.comLisata Therapeutics partners with Haystack Oncology to advance pancreatic cancer therapy researchJuly 18, 2024 | proactiveinvestors.comHaystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer TherapyJuly 18, 2024 | globenewswire.comLisata Therapeutics completes enrollment in Phase 2a BOLSTER trial for certepetide in bile duct cancerJuly 16, 2024 | proactiveinvestors.comLisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line CholangiocarcinomaJuly 16, 2024 | globenewswire.comLisata's certepetide showing promising early results as cholangiocarcinoma treatment – ICYMIJuly 13, 2024 | proactiveinvestors.comLisata Therapeutics shares promising pre-clinical dataJuly 10, 2024 | proactiveinvestors.comLisata Therapeutics' Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical ModelJuly 10, 2024 | globenewswire.comLisata Therapeutics CEO discusses enrollment milestone for pancreatic cancer trialJune 18, 2024 | proactiveinvestors.comLisata Therapeutics completes pancreatic cancer cohort enrollment in CENDIFOX trialJune 13, 2024 | proactiveinvestors.com Get Lisata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Tesla Execs are Freaking Out (Ad)It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss. Click here to get the details. LSTA Media Mentions By Week LSTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LSTA News Sentiment▼1.000.47▲Average Medical News Sentiment LSTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LSTA Articles This Week▼61▲LSTA Articles Average Week Get Lisata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Kentucky First Federal Bancorp News Today Eliem Therapeutics News Today Cabaletta Bio News Today Nuvectis Pharma News Today Oramed Pharmaceuticals News Today Annovis Bio News Today Eupraxia Pharmaceuticals News Today Quince Therapeutics News Today Assertio News Today Invivyd News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LSTA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LSTA Stock Alerts